MergerAug 13, 2026, 04:13 PM
Matinas BioPharma to Merge with GH Power, Sells Subsidiary
AI Summary
Matinas BioPharma Holdings, Inc. reported a net loss of $(1.326) million for the second quarter of 2026 and $(3.247) million for the first six months of 2026. With cash and cash equivalents of $761 thousand and an accumulated deficit of $214.034 million as of June 30, 2026, the company issued a going concern warning. Subsequent to the quarter, Matinas entered into a Business Combination Agreement with GH Power Inc. and a Stock Purchase Agreement to sell its Nanotechnologies subsidiary. The company also secured additional funding through a Series D Financing and a Warrant Inducement, raising $575 thousand and $2.323 million, respectively.
Key Highlights
- Net loss for the three months ended June 30, 2026, was $(1.326) million, compared to $(5.245) million in the prior year.
- Net loss for the six months ended June 30, 2026, was $(3.247) million, compared to $(6.901) million in the prior year.
- Cash and cash equivalents totaled $761 thousand as of June 30, 2026.
- The accumulated deficit reached $214.034 million as of June 30, 2026.
- The company issued a going concern warning due to insufficient cash to fund planned operations for at least twelve months.
- Entered a Business Combination Agreement with GH Power Inc. in July 2026, making Matinas a wholly owned subsidiary of Pubco.
- Signed a Stock Purchase Agreement in July 2026 to sell its subsidiary Nanotechnologies to Azurity Pharmaceuticals, Inc.
- Received net proceeds of $575 thousand from a Series D Financing and $2.323 million from a Warrant Inducement in July 2026.
Price Impact
More from MTNB